TY - JOUR
T1 - Upregulation of fecal cytokeratin 19 is associated with prognosis in older colorectal cancer patients
AU - Yang, Ruey Neng
AU - Yang, Shung Haur
AU - Chang, Chun Chao
AU - Chien, Chih Cheng
AU - Pan, Shiann
AU - Huang, Chi Jung
PY - 2010/10/1
Y1 - 2010/10/1
N2 - The upregulation of fecal cytokeratin 19 (CK19) correlates with age and metastatic status in human colorectal cancer (CRC). To further explore its clinical significance in older patients (>60 years), their fecal CK19 was measured by quantitative reverse transcription-polymerase chain reaction. Differences in CK19 transcripts were compared using the nonparametric Mann-Whitney U test. Clinical significance was assessed with the chi-squared test and a binary logistic regression model. The association between overall survival and expressions of fecal CK19 in combination with other serum markers, carcinoembryonic antigen and carbohydrate antigen 19-9 (CA19-9), was evaluated using the Kaplan-Meier method. In these older groups, CRC patients had significantly higher median fecal CK19 expression (p=0.006) than controls. The highest risk of CRC (odds ratio, 5.8; 95% confidence interval, 2.3-14.7; p
AB - The upregulation of fecal cytokeratin 19 (CK19) correlates with age and metastatic status in human colorectal cancer (CRC). To further explore its clinical significance in older patients (>60 years), their fecal CK19 was measured by quantitative reverse transcription-polymerase chain reaction. Differences in CK19 transcripts were compared using the nonparametric Mann-Whitney U test. Clinical significance was assessed with the chi-squared test and a binary logistic regression model. The association between overall survival and expressions of fecal CK19 in combination with other serum markers, carcinoembryonic antigen and carbohydrate antigen 19-9 (CA19-9), was evaluated using the Kaplan-Meier method. In these older groups, CRC patients had significantly higher median fecal CK19 expression (p=0.006) than controls. The highest risk of CRC (odds ratio, 5.8; 95% confidence interval, 2.3-14.7; p
UR - http://www.scopus.com/inward/record.url?scp=78650145276&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78650145276&partnerID=8YFLogxK
U2 - 10.1089/gtmb.2010.0047
DO - 10.1089/gtmb.2010.0047
M3 - Article
C2 - 20854102
AN - SCOPUS:78650145276
SN - 1945-0265
VL - 14
SP - 703
EP - 708
JO - Genetic Testing and Molecular Biomarkers
JF - Genetic Testing and Molecular Biomarkers
IS - 5
ER -
